Literature DB >> 29313798

Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.

Piercarla Schinco1, Giancarlo Castaman2, Antonio Coppola3, Dorina Cultrera4, Cosimo Ettorre5, Anna C Giuffrida6, Emanuela Marchesini7, Renato Marino5, Marta Milan8, Claudio Molinari9, Simona M Siboni10, Ezio Zanon8, Augusto B Federici11.   

Abstract

Recent advances in the care of von Willebrand's disease (vWD) have allowed the majority of patients to be managed adequately. Even in the more severe forms, it is now possible to control recurrent bleeding through secondary long-term prophylaxis with von Willebrand factor-containing concentrates. Moreover, in the setting of surgical prophylaxis, the combination of interdisciplinary management and close patient monitoring yields a positive outcome in nearly all cases, although safety concerns remain. In clinical practice, the effectiveness of therapy is hindered by the difficulties in making a rapid, yet accurate diagnosis, in identifying the subgroup of bleeders who may benefit most from a specific strategy, and in selecting the optimal product and regimen.Since specific guidelines for heavy bleeders requiring short- and long-term prophylaxis are still lacking, sharing the experience of experts dealing with vWD patients on a daily basis is crucial to fill gaps in information relating to patient management. To address this important issue, 13 Italian haematologists met in Milan on April, 2, 2016 and in Florence on July, 9, 2016. A 30-question survey constituted the input to discuss (i) optimisation of the diagnostic workflow for vWD, (ii) the characteristics of patients who may benefit from secondary long-term prophylaxis (in particular with the purified von Willebrand factor concentrate with a low content of factor VIII), (iii) the key elements to consider when selecting a concentrate and (iv) the pre-operative and post-operative management of vWD patients. A summary of the main points covered is provided in this report.

Entities:  

Mesh:

Year:  2017        PMID: 29313798      PMCID: PMC6034771          DOI: 10.2450/2017.0354-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  49 in total

1.  Summary of a workshop on potency and dosage of von Willebrand factor concentrates.

Authors:  A C Chang; M E Rick; L Ross Pierce; M J Weinstein
Journal:  Haemophilia       Date:  1998       Impact factor: 4.287

2.  The von Willebrand disease prophylaxis network: exploring a treatment concept.

Authors:  E Berntorp; T Abshire
Journal:  J Thromb Haemost       Date:  2006-11       Impact factor: 5.824

3.  ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.

Authors:  F Rodeghiero; A Tosetto; T Abshire; D M Arnold; B Coller; P James; C Neunert; D Lillicrap
Journal:  J Thromb Haemost       Date:  2010-09       Impact factor: 5.824

4.  Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network.

Authors:  Elena Holm; Thomas C Abshire; Joel Bowen; M Teresa Álvarez; Paula Bolton-Maggs; Manuel Carcao; Augusto B Federici; Joan Cox Gill; Susan Halimeh; Christine Kempton; Nigel S Key; Peter Kouides; Alice Lail; Andrea Landorph; Frank Leebeek; Michael Makris; Pier Mannucci; Eveline P Mauser-Bunschoten; Diane Nugent; Leonard A Valentino; Rochelle Winikoff; Erik Berntorp
Journal:  Blood Coagul Fibrinolysis       Date:  2015-06       Impact factor: 1.276

5.  The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD.

Authors:  Giancarlo Castaman; Alberto Tosetto; Anne Goodeve; Augusto B Federici; Stefan Lethagen; Ulrich Budde; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; David Habart; Frank Hill; Ian Peake; Francesco Rodeghiero
Journal:  Br J Haematol       Date:  2010-08-25       Impact factor: 6.998

6.  Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

Authors:  Pier M Mannucci; Juan Chediak; Wahid Hanna; John Byrnes; Marlies Ledford; Bruce M Ewenstein; Anastassios D Retzios; Barbara A Kapelan; Richard S Schwartz; Craig Kessler
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

7.  von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.

Authors:  J C Gill; A Shapiro; L A Valentino; J Bernstein; C Friedman; W L Nichols; M Manco-Johnson
Journal:  Haemophilia       Date:  2011-04-27       Impact factor: 4.287

8.  Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.

Authors:  K J Pasi; P W Collins; D M Keeling; S A Brown; A M Cumming; G C Dolan; C R M Hay; F G H Hill; M Laffan; I R Peake
Journal:  Haemophilia       Date:  2004-05       Impact factor: 4.287

9.  A comparative in vitro evaluation of six von Willebrand factor concentrates.

Authors:  S Lethagen; M Carlson; A Hillarp
Journal:  Haemophilia       Date:  2004-05       Impact factor: 4.287

10.  In vitro study of a triple-secured von Willebrand factor concentrate.

Authors:  C Mazurier; M Poulle; B Samor; L Hilbert; S Chtourou
Journal:  Vox Sang       Date:  2004-02       Impact factor: 2.144

View more
  2 in total

1.  Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report.

Authors:  Flora Peyvandi
Journal:  Blood Transfus       Date:  2017-05-26       Impact factor: 3.443

2.  Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database.

Authors:  Jonathan C Roberts; Lynn M Malec; Imrran Halari; Sarah A Hale; Abiola Oladapo; Robert F Sidonio
Journal:  Haemophilia       Date:  2021-11-10       Impact factor: 4.263

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.